secwatch.observer — SEC 8-K summary
======================================

Issuer:     Karyopharm Therapeutics Inc. (KPTI)
CIK:        0001503802
Form:       8-K
Filed at:   2024-02-29T23:59:59+00:00
Accession:  0001193125-24-051845
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Karyopharm reports FY2023 total rev $146M, XPOVIO net $112M; guides 2024 total $140-160M
--------------------------------------------------------------------------------

- Full year 2023 total revenue $146.0M (down from $157.1M YoY); net loss $143.1M ($1.25/sh) vs $165.3M loss in 2022.
- Q4 2023 XPOVIO net product revenue $25.1M; full year $112.0M, down ~7% YoY due to competition and PAP utilization.
- Three pivotal Phase 3 top-line readouts expected in 2025: endometrial cancer, myelofibrosis, multiple myeloma.
- 2024 guidance: total revenue $140-160M, XPOVIO net $100-120M, R&D+SG&A $260-280M, cash runway to late 2025.
- Cash, equivalents and investments $192.4M as of Dec 31, 2023 vs $279.7M a year earlier.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1503802/000119312524051845/0001193125-24-051845-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1503802/000119312524051845/d774952d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-051845

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer